Dr Biolyse^® Bioelectrical Epigenetic Programming (BEP) System 

Biophysically-Driven Translational Medicine Technology

Dr Biolyse^® is a pioneering medical device technology engineered to emulate the highly conserved endogenous bioelectrical architecture and natural restoration processes of mammalian biology (biomimetics); having successfully completed its pre-clinical and clinical (animal and human) research phases, it has initiated its global regulatory approval pathway, which is dynamically supported by ongoing advanced R&D initiatives.

The system serves as the clinical implementer of Bioelectrical Epigenetic Programming (BEP) technology, which operates by restructuring epigenetic signaling mechanisms through the precise regulation and modulation of cellular ion channels at the single-cell level.

By delivering controlled and unique extrinsic bioelectrical algorithms, Dr Biolyse® activates targeted cellular structures, thereby rewiring ionic equilibria and signaling pathways. This biophysical modulation reprograms the transcriptional networks underlying complex biochemical pathologies at the cellular level, activating the organism’s autonomous repair and defense mechanisms. Deploying an adaptive and flexible cellular response network against evolving pathological profiles, this technology represents a next-generation paradigm designed to guide the system back to allostatic homeostasis with stability validated by universal biostatistical frameworks.